Insured patients who had gastric bypass surgery paid $704 less in out-of-pocket costs over two years compared to those taking semaglutide or tirzepatide.
$704 lessTwo-year out-of-pocket savings for gastric bypass patients compared to GLP-1 drug users
What the researchers found
Over two years, insured patients who had Roux-en-Y gastric bypass (RYGB) surgery paid $704 less in out-of-pocket healthcare costs than matched patients treated with GLP-1 receptor agonists (semaglutide or tirzepatide) for type 2 diabetes and obesity.
In the first year, costs were similar between groups ($2,301 for RYGB vs. $2,179 for GLP-1 RAs, p=0.15). But in the second year, RYGB costs dropped significantly to $1,277 while GLP-1 RA costs remained at $2,104 (p<0.01), driven by the ongoing prescription costs of the medications.
Why it matters
The debate over surgery versus GLP-1 drugs for obesity and diabetes often focuses on clinical outcomes. This study adds a critical financial dimension: while GLP-1 drugs avoid surgery, their ongoing costs accumulate and may exceed the one-time surgical expense within two years, placing a greater financial burden on patients.
The numbers in context
n=1,012 matched pairs · Year 1: RYGB $2,301 vs GLP-1 $2,179 (p=0.15) · Year 2: RYGB $1,277 vs GLP-1 $2,104 (p<0.01) · 2-year difference: $704 lower for RYGB (p<0.01)
How the study worked
Retrospective matched analysis using the 2017–2023 Merative claims database. 1,012 pairs of adults with severe obesity and type 2 diabetes were matched on demographics, obesity status, comorbidities, and baseline costs. One group had RYGB without GLP-1 RA use; the other received semaglutide or tirzepatide for at least 2 years without any bariatric surgery. Out-of-pocket costs (outpatient services, inpatient admissions, prescriptions) were compared at 1 and 2 years using paired t-tests.
Who was studied
1,012 matched pairs of insured U.S. adults with severe obesity and type 2 diabetes (35% male)
What this study cannot tell us
This is a retrospective claims analysis, not a randomized trial, so unmeasured confounders may influence results. The study only captures 2 years of follow-up — the cost gap may widen further over time, or surgical complications could emerge later. It also only measures direct patient costs, not total healthcare system costs or clinical outcomes.
How to read the evidence
This is a well-designed matched retrospective analysis using a large claims database with over 1,000 matched pairs. While not a randomized trial, the careful matching on demographics and baseline costs strengthens the comparison, warranting a moderate evidence grade.
When this study was published
Published in 2026 using data through 2023, this is highly current research addressing one of the most pressing questions in obesity treatment economics.
The bigger picture
As GLP-1 receptor agonists become the dominant treatment for obesity and diabetes, questions about their long-term affordability are intensifying. This study suggests that bariatric surgery, despite its upfront costs and invasiveness, may be more economical for patients over time — a finding with major implications for insurance coverage decisions and treatment guidelines.
Questions still open
- How does the cost comparison look at 5 or 10 years, given that GLP-1 drugs require indefinite use?
- Would generic or biosimilar GLP-1 drugs change this cost calculation when they become available?
- How do clinical outcomes (weight loss maintenance, diabetes remission) compare between these groups alongside the cost differences?
Common questions
Why does gastric bypass become cheaper than GLP-1 drugs over time?
Does this mean surgery is better than GLP-1 drugs?
Read the original research
Roux-en-Y Gastric Bypass Compared to Glucagon-Like Peptide-1 Receptor Agonists is Associated with Lower Out-of-Pocket Costs in Insured Patients with Type 2 Diabetes and Obesity: A Matched Analysis Over Two Years.
Obesity surgery, 36(2), 376-385
Citation
Thiyagarajan, Sibi; Wall-Wieler, Elizabeth; Liu, Yuki; Zheng, Feibi; Edwards, Michael. (2026). Roux-en-Y Gastric Bypass Compared to Glucagon-Like Peptide-1 Receptor Agonists is Associated with Lower Out-of-Pocket Costs in Insured Patients with Type 2 Diabetes and Obesity: A Matched Analysis Over Two Years.. Obesity surgery, 36(2), 376-385. https://doi.org/10.1007/s11695-025-08467-3